Abstract COVID-19 Vaccine Clinical Development Team The USG enterprise to develop and optimize vaccine prevention modalities for SARS CoV-2 incorporates the DAIDS HVTN as a key partner in strategic development, research prioritization and execution, landscape analysis for future directions and analysis of outcomes. Dr. Robb has co-chaired and participated in the USG Vaccine Development Team for clinical research along with the PI and others within the HVTN. The administrative amendment to CTU funding to HJF will sustain Dr. Robb’s role in this capacity.